UY32896A - Composiciones de enzimas pancreáticas y métodos para tratar pancreatitis e insuficiencia pancreática - Google Patents

Composiciones de enzimas pancreáticas y métodos para tratar pancreatitis e insuficiencia pancreática

Info

Publication number
UY32896A
UY32896A UY0001032896A UY32896A UY32896A UY 32896 A UY32896 A UY 32896A UY 0001032896 A UY0001032896 A UY 0001032896A UY 32896 A UY32896 A UY 32896A UY 32896 A UY32896 A UY 32896A
Authority
UY
Uruguay
Prior art keywords
pancreatic
compositions
methods
enzymes
insufficiency
Prior art date
Application number
UY0001032896A
Other languages
English (en)
Inventor
Gopi M Venkatesh
Perrett Stephen
Ruth Thieroff-Ekerdt
Efthymiopoulos Konstantino
Original Assignee
Eurand Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43730817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY32896(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eurand Pharmaceuticals Ltd filed Critical Eurand Pharmaceuticals Ltd
Publication of UY32896A publication Critical patent/UY32896A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Las composiciones de la presente invención, que comprenden la combinación de perlas entéricamente revestidas y no revestidas que contienen enzima pancreática, son útiles para tratar o prevenir dolor pancreático, y opcionalmente trastornos asociados con deficiencias de enzimas digestivas.
UY0001032896A 2009-09-17 2010-09-17 Composiciones de enzimas pancreáticas y métodos para tratar pancreatitis e insuficiencia pancreática UY32896A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24346709P 2009-09-17 2009-09-17

Publications (1)

Publication Number Publication Date
UY32896A true UY32896A (es) 2011-02-28

Family

ID=43730817

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032896A UY32896A (es) 2009-09-17 2010-09-17 Composiciones de enzimas pancreáticas y métodos para tratar pancreatitis e insuficiencia pancreática

Country Status (23)

Country Link
US (2) US8784884B2 (es)
EP (1) EP2477645B1 (es)
JP (1) JP5877399B2 (es)
KR (1) KR101771752B1 (es)
CN (2) CN102630164B (es)
AR (1) AR078291A1 (es)
AU (1) AU2010295494B2 (es)
BR (1) BR112012005837A8 (es)
CA (1) CA2774269C (es)
CL (1) CL2012000658A1 (es)
CO (1) CO6531419A2 (es)
ES (1) ES2690661T3 (es)
HK (1) HK1218886A1 (es)
IL (2) IL218656A (es)
MX (1) MX2012003214A (es)
MY (1) MY161843A (es)
NZ (1) NZ599143A (es)
RU (1) RU2570376C2 (es)
SA (1) SA110310695B1 (es)
TW (2) TWI572372B (es)
UY (1) UY32896A (es)
WO (1) WO2011035079A1 (es)
ZA (1) ZA201202761B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
ES2674681T3 (es) 2007-02-20 2018-07-03 Allergan Pharmaceuticals International Limited Composiciones estables de enzimas digestivas
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
KR20140019292A (ko) 2010-10-01 2014-02-14 아프탈리스 파르마 리미티드 장용 코팅된 저 강도 췌장 리파제 제제
WO2013021359A1 (en) 2011-08-08 2013-02-14 Aptalis Pharma Ltd. Method for dissolution testing of solid compositions containing digestive enzymes
WO2015020943A2 (en) 2013-08-09 2015-02-12 Aptalis Pharma Ltd. Digestive enzyme composition suitable for enteral administration
WO2015193730A1 (en) 2014-06-19 2015-12-23 Aptalis Pharma Ltd. Methods for removing viral contaminants from pancreatic extracts
FR3079146B1 (fr) * 2018-03-23 2020-04-17 Karim Ioualalen Formulation gastroprotectrice de complexes d’enzymes permettant de restaurer la fonction digestive.
US20230138700A1 (en) * 2020-03-30 2023-05-04 Jai WALL Combined animal-derived and synthetically produced pancreatic enzyme replacement therapy

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509866A (en) 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
US4447412A (en) 1983-02-01 1984-05-08 Bilton Gerald L Enzyme-containing digestive aid compostions
US5302400A (en) 1992-06-22 1994-04-12 Digestive Care Inc. Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids
US5460812A (en) 1992-06-22 1995-10-24 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5578304A (en) 1992-06-22 1996-11-26 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5260074A (en) 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
DE4227385A1 (de) 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
WO1997028788A1 (en) 1996-02-09 1997-08-14 Quadrant Holdings Cambridge Ltd. Solid formulations containing trehalose
US5750104A (en) 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US20010046493A1 (en) 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
CN1156308C (zh) * 2002-04-19 2004-07-07 北京世诺医药科技有限公司 多酶组合胶囊
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
WO2004071374A2 (en) 2003-02-11 2004-08-26 Torrent Pharmaceuticals Limited Once a day orally administered pharmaceutical compositions
WO2005042012A1 (en) * 2003-10-29 2005-05-12 Altus Pharmaceuticals Inc. Non-pancreatic proteases for controlling plasma cholecystokinin (cck) concentration and for treating pain
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US7470435B2 (en) 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
PL1729797T3 (pl) 2004-03-22 2009-02-27 Abbott Laboratories Gmbh Doustne kompozycje farmaceutyczne produktów zawierających lipazę, a zwłaszcza pankreatynę, zawierające środki powierzchniowo czynne
CA2586222A1 (en) * 2004-05-24 2005-12-08 Novozymes A/S Enzymes for pharmaceutical use
ATE474592T1 (de) 2004-10-14 2010-08-15 Altus Pharmaceuticals Inc Zusammensetzungen enthaltend lipase, protease und amylase zur behandlung von pankreasinsuffizienz
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US20090047266A1 (en) * 2005-06-24 2009-02-19 Novozymes A/S Lipases for Pharmaceutical Use
US20070025977A1 (en) 2005-07-21 2007-02-01 Mulberg Andrew E Method of treating steatorrhea in infants
CN101233229B (zh) 2005-07-29 2013-05-01 雅培实验室有限公司 制备消毒的胰酶粉末的方法
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US8071089B2 (en) 2005-11-01 2011-12-06 Bio-Cat, Inc. Composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrosis as well as people suffering from pancreatic lipase insufficiency
MX2008015031A (es) * 2006-05-26 2008-12-05 Nestec Sa Metodos de uso y composiciones nutritivas de extracto de touchi.
US20080199448A1 (en) * 2007-02-16 2008-08-21 Ross Mairi R Enzyme composition for improving food digestion
ES2674681T3 (es) * 2007-02-20 2018-07-03 Allergan Pharmaceuticals International Limited Composiciones estables de enzimas digestivas
US20090117180A1 (en) 2007-02-20 2009-05-07 Giovanni Ortenzi Stable digestive enzyme compositions
US20110171294A1 (en) 2008-09-30 2011-07-14 Dsm Ip Assets B.V. Enzyme composition and application thereof in the treatment of pancreatic insufficiency

Also Published As

Publication number Publication date
US20140287035A1 (en) 2014-09-25
AU2010295494B2 (en) 2014-09-25
CN102630164A (zh) 2012-08-08
US8784884B2 (en) 2014-07-22
CA2774269A1 (en) 2011-03-24
AR078291A1 (es) 2011-10-26
TW201113052A (en) 2011-04-16
TWI572372B (zh) 2017-03-01
RU2012113253A (ru) 2013-10-27
AU2010295494A1 (en) 2012-03-29
IL245875A0 (en) 2016-07-31
IL218656A0 (en) 2012-05-31
CL2012000658A1 (es) 2012-09-28
US20160051472A9 (en) 2016-02-25
CO6531419A2 (es) 2012-09-28
CN105214073A (zh) 2016-01-06
ZA201202761B (en) 2012-12-27
WO2011035079A1 (en) 2011-03-24
SA110310695B1 (ar) 2014-11-26
KR101771752B1 (ko) 2017-08-25
MY161843A (en) 2017-05-15
TW201639545A (zh) 2016-11-16
CA2774269C (en) 2017-03-21
BR112012005837A2 (pt) 2017-05-30
NZ599143A (en) 2014-05-30
BR112012005837A8 (pt) 2017-10-10
US20110064799A1 (en) 2011-03-17
JP5877399B2 (ja) 2016-03-08
KR20120100915A (ko) 2012-09-12
CN102630164B (zh) 2015-09-16
EP2477645A4 (en) 2014-06-25
MX2012003214A (es) 2012-08-01
EP2477645A1 (en) 2012-07-25
JP2013505255A (ja) 2013-02-14
ES2690661T3 (es) 2018-11-21
RU2570376C2 (ru) 2015-12-10
EP2477645B1 (en) 2018-08-15
IL218656A (en) 2017-12-31
HK1218886A1 (zh) 2017-03-17

Similar Documents

Publication Publication Date Title
UY32896A (es) Composiciones de enzimas pancreáticas y métodos para tratar pancreatitis e insuficiencia pancreática
PH12015502362A1 (en) Certain chemical entities, compositions and methods
BRPI0516515A (pt) composições contendo lipase, protease e amilase para o tratamento da insuficiência pancreática
CR20140422A (es) Composiciones de enzima digestiva estable
EA201170349A1 (ru) Модуляторы mif
GB2511713A (en) Methods of treating behavioral symptoms of neurological and mental disorders
HK1175395A1 (en) Use of hsp70 as a regulator of enzymatic activity hsp70
MY168762A (en) Certain chemical entities, compositions and methods
MX2012007684A (es) Modificacion covalente ligando dirigida de proteina.
MX342128B (es) Compuestos farmaceuticos.
EP2494059A4 (en) USE OF METHYSULFONYLMETHANE (MSM) FOR MODULATION OF MICROBIAL ACTIVITY
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
GB0920703D0 (en) Compositions containing satiogens and methods of use
WO2011140202A3 (en) Mif modulators
EA201200793A1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
BR112016001289A2 (pt) pancreatina de alta atividade (ha-pancreatina), composição farmacêutica de alta potência, processo para preparação da ha-pancreatina com atividade de lipase específica de, pelo menos, cerca de 120 ui usp/mg e método de tratamento de um paciente que apresenta uma condição fisiológica associada à insuficiência enzimática pancreática
GB201202561D0 (en) Treatment of skin disorders
ECSP088764A (es) Métodos para tratar trastornos cognitivos y otros afines
WO2011106785A3 (en) Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
WO2009136997A3 (en) Inhibitors of human cathepsin l, cathepsin b, and cathepsin s
WO2011097327A3 (en) Compositions and methods of modulating receptor protein tyrosine phosphatases
WO2011116351A3 (en) Methods and compositions for the treatment of cancer
ES2514140A1 (es) Uso del inhibidor de sulfatasas esteroideas STX64 para el tratamiento del envejecimiento

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20210602